A Randomized, Double-blind, Placebo-controlled Study of the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Oral Doses of CFTX-1554 in Healthy Subjects, With Comparison of Intake of CFTX-1554 as Liquid Formulation and as Capsule, and After a High-fat Breakfast Versus Fasted
Latest Information Update: 01 Aug 2024
At a glance
- Drugs CFTX-1554 (Primary)
- Indications Neuropathic pain
- Focus Adverse reactions; First in man
- Sponsors Confo Therapeutics
- 29 Jul 2024 According to a Confo Therapeutics media release, the comapany announces EUR 60M series B financing to advance pipeline of Novel GPCR-Modulating therapies into clinical development the proceeds will be used to advance two, wholly owned programs through Phase 1.
- 01 Sep 2023 Status changed from recruiting to completed.
- 10 Mar 2022 According to a Confo Therapeutics media release, first subjects have been dosed in this study.